title: Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients.
abstract: OBJECTIVE
  To compare the clinic-pathologic variables and the prognosis of endometrial cancer in patients with and without previous breast cancer, with and without Tamoxifen.
  
  
  METHODS
  We analyzed patients treated for an endometrial carcinoma from 1994 to 2004: patients without breast cancer (group 1), patients with a previous breast cancer without tamoxifen (group 2) and patients treated for breast cancer with tamoxifen (group 3). Survival rates were calculated according to Kaplan-Meier method and compared using a Log rank test, multivariate analysis was performed with a Cox regression model.
  
  
  RESULTS
  363 patients were analyzed. 80 patients had a previous history of breast cancer (43 received tamoxifen). Although it was not statistically significant, more carcinosarcomas were observed in patients in group 3 than patients in groups 1 and 2 (11.7% versus 4.2% and 5.4% respectively, p = 0.17).) Median follow-up was 87 months [2-185]. 5-year overall survival rate was respectively in groups 1, 2 and 3: 82%, 73.2%, and 61% (p = 0.0006). 5-year local relapse-free survival rate was respectively: 95.9%, 93.1% and 82.5% (p = 0.02). In multivariate analysis, factors affecting overall survival rate were: age ≥65 ans (HR 3.62, p < 0.0001), FIGO stage (HR 3.33 p < 0.0001 for locally advanced stage versus early stage, HR 8.87 p = 0.03 for distant extension versus early stage), and group 3 (HR 2.83 p < 0.001 versus group 1).
  
  
  CONCLUSIONS
  Patients with endometrial cancer previously treated for breast cancer show a worse prognostic, particularly if they reveived tamoxifen.
authors.affiliation: Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Electronic address: nphuongvi@hotmail.com.
authors.forename: C
authors.initials: C
authors.lastname: Ngô
authors.affiliation: Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Brugier
authors.affiliation: Department of Biostatistics, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Plancher
authors.affiliation: Department of Radiotherapy, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: de la Rochefordière
authors.affiliation: Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Alran
authors.affiliation: Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: J G
authors.initials: JG
authors.lastname: Féron
authors.affiliation: Department of Medical Imaging, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Malhaire
authors.affiliation: Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Scholl
authors.affiliation: Department of Pathology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: X
authors.initials: X
authors.lastname: Sastre
authors.affiliation: Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Rouzier
authors.affiliation: Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Fourchotte
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D018262:Adenocarcinoma, Clear Cell / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D018269:Carcinoma, Endometrioid / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy; D018275:Carcinoma, Lobular / Q000188:drug therapy; D018277:Carcinoma, Mucoepidermoid / Q000473:pathology*; D002296:Carcinosarcoma / Q000473:pathology*; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000473:pathology*; D011379:Prognosis; D013629:Tamoxifen / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen
keywords: Breast cancer; Endometrial cancer; Prognosis of endometrial cancer; Tamoxifen